Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



(Incorporated in the Cayman Islands with limited liability) (Stock Code : 01110)

PROFIT GUARANTEE IN RESPECT OF THE ACQUISITION OF 55% EQUITY INTEREST IN SHENZHEN DONG DI XIN TECHNOLOGY COMPANY LIMITED*

References are made to (i) the announcements of Kingworld Medicines Group Limited (the "**Company**") dated 8 May 2014, 31 July 2014, 30 September 2014, 25 November 2014 and 13 February 2015, respectively, (ii) circular of the Company dated 31 December 2014 (the "**Circular**"), and (iii) the poll result announcement of the Company dated 23 January 2015, in relation to the Cooperation Agreement and the transactions contemplated thereunder. Capitalised terms used in this announcement shall have the same meanings as those defined in the Circular, unless defined herein or the context requires otherwise.

Pursuant to the Cooperation Agreement, the Vendors have guaranteed to the Purchaser that after the completion of the Equity Transfer, the Net Profit will not be less than RMB32,047,000, RMB35,252,000 and RMB38,777,000 (the "Guaranteed **Profits**") for the three years ending 31 December 2015, 2016 and 2017, respectively.

The Board is pleased to announce that the Net Profit for the two years ended 31 December 2015 and 2016 amounted to approximately RMB35,132,000 and RMB43,240,000 respectively, and accordingly have exceeded the Guaranteed Profits for the two years.

The Company will publish an announcement in respect of the fulfilment or non-fulfilment of the Guaranteed Profits for the year ending 31 December 2017.

By order of the Board Kingworld Medicines Group Limited Zhao Li Sheng Chairman

Hong Kong, 22 June 2017

As at the date of this announcement, the executive Directors are Mr. Zhao Li Sheng, Ms. Chan Lok San, Mr. Zhou Xuhua, the non-executive Director is Mr. Zhang Yi and the independent non-executive Directors are Mr. Duan Jidong, Mr. Zhang Jianbin and Mr. Wong Cheuk Lam.

*For identification purpose only